Keep up to date with our latest partnering deals and highlights

Below is a selection of news releases describing recent deals completed by AstraZeneca and our biologics arm, MedImmune.

Monday, 14 January 2013
AstraZeneca and Vanderbilt University collaborate to develop novel treatments for major brain disorders Today AstraZeneca and Vanderbilt University announced they have signed a research collaboration agreement to identify candidate drugs aimed at treating psychosis and other neuropsychiatric symptoms associated with major brain diseases such as Alzheimer’s disease and schizophrenia.
Wednesday, 9 January 2013
Kicking off 2013 with strong presence at 31st annual JPMorgan event As the first key partnering conference of 2013, JPM proved a solid launch-pad for building on new and existing business development relationships and reinforcing AstraZeneca’s position as the partner of choice.
Thursday, 27 December 2012
CytImmune and AstraZeneca to Research Potential New Nanomedicine Rockville, MD and Waltham, MA –December 27, 2012-CytImmune and AstraZeneca have entered into an agreement to study the feasibility of a new cancer nanomedicine that will bind an oncology compound from AstraZeneca to CytImmune’s CYT-6091 nanomedicine platform.
Download our brochure

Download your comprehensive guide to partnering with us.


Meet us at an event

Calendar iconView our full event calendar to see events we are attending.

View calendar